Methods: A group of 66 patients with NSCLC at first diagnosis was included. In this study, using a quantitative CT imaging-based approach, we aimed to investigate the differences of abdominal adipose tissue distribution in patients with non-small cell lung cancer (NSCLC) according to gender. Overfat and obese patients and those who lose weight during chemotherapy were more subject to weight and fat mass gain during endocrine therapy.Д«ackground: Lung cancer is a malignant tumor with high lethality, responsible for about 28% of all cancer deaths. Conclusion: Endocrine therapy appears as a pivotal period in weight and body composition management. 031) and was characterized by an increase in total lean body mass, mainly localized in the trunk region. The average gain was the same as that during the endocrine therapy period (2.0 В± 5.4 kg P =. In the overall period of adjuvant cancer treatment, 30% of the population gained > 5% of their initial weight. The factors linked to fat mass gain included an excess fat mass (в‰Ґ 36%) before treatment and weight loss during chemotherapy. During this period, the fat mass, lean body mass, and body water increased. The overall average gain was 2.0 В± 5.5 kg (P =. Results: During endocrine therapy, 5 of the 33 patients (15.2%) lost weight and 12 (36.4%) gained weight. The Hospital Anxiety and Depression questionnaire and the short version of the International Physical Activity Questionnaire were also administered. Body water was assessed using multifrequency bioelectrical impedance analysis. Patients and Methods: Dual-energy x-ray absorptiometry was used to measure the fat and lean body mass. The present study assessed the evolution of weight and body composition among 33 postmenopausal breast cancer patients receiving endocrine therapy after standard adjuvant chemotherapy that included taxanes. The long-term evolution of body composition during adjuvant treatment for breast cancer, in particular, endocrine therapy, is not well known, and new data on this topic are required. Background: Weight changes during adjuvant treatment for early-stage breast cancer has been associated with a poor prognosis. With a median follow-up of 3 years after chemotherapy, our results showed a small weight gain but highlighted that the initial fatness in postmenopausal breast cancer patients promotes a longitudinal 3-year weight gain. The study of body composition during adjuvant treatment is key to understanding this interaction. Weight variations during treatment have been associated with a poor prognosis for early-stage breast cancer patients. Because this pattern of fat distribution is associated with metabolic disorders, attention must be paid to these clinical manifestations in patients during their follow-up management. In our study, therapy with AI in breast cancer patients was accompanied with a change in fat distribution to relatively greater VAT/SAT ratio in patients, regardless of whether they gained or lost weight after therapy. Modification of VAT/SAT ratio was observed (from 1.38 to 1.69) in all subjects, reflecting a relative increased volume of VAT (mean, 18%) and slight mean reduction of SAT (mean 1.9%).

Two groups of patients were observed those with an increase in TAAT and those with a decrease. Percentages were calculated for change of TAAT, VAT, and SAT. SAT was manually segmented and VAT was determined as TAAT - SAT. Abdominal fat distribution was automatically calculated using a workstation that obtained total abdominal adipose tissue (TAAT) area (mm(3)). Patients were evaluated using CT before and after at least 6 months of AI therapy with imaging follow-up of 4.3 В± 2.2 years. Sixty-four consecutive patients who were receiving adjuvant AI therapy were included in this study. The purpose of this study was to describe modification of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) distributions in breast cancer patients after aromatase inhibitor (AI) therapy using computed tomography (CT) volumetric measurement of abdominal body fat distribution.

Mauno pepponen